Search
Artiva's cell therapy approach to autoimmune conditions is unique because it is NK cell based, donor derived, and there is no engineering of the cells - they believe the benefit is already in the data
CEO Fred Aslan walks us through this unique program and its potential advantages, which include that it can be administered in the community setting and can also be redosed if necessary. A 350 patient randomized registration trial in rheumatoid arthritis will be underway this year. Coverage brought to you by
Jun 25
Checking in with Artiva CEO Fred Aslan after the NK cell focused company's $167 million IPO
He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is...
Aug 15, 2024
Using NK cell therapies for autoimmune disease and cancer with Artiva's CEO
Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity.
Mar 1, 2024
.png){kind=logo}